Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.Ravi A. Madan, Peter L. Choyke, Melissa L. Abel et al.|Journal of Clinical Oncology|2025Cited by 0
2393P Prospective monitoring of prostate specific membrane antigen (PSMA) in biochemically recurrent prostate cancer (BCR): Preliminary data from 1 Year follow-upRavi A. Madan, Peter Choyke, Melissa L. Abel et al.|Annals of Oncology|2025Cited by 0
Association of prostate specific antigen (PSA) doubling time (DT) and prostate specific membrane antigen (PSMA) findings in biochemically recurrent prostate cancer (BCR).Melissa L. Abel, Ravi A. Madan, Esther Mena et al.|Journal of Clinical Oncology|2026Cited by 0
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.Ravi A. Madan, Melissa L. Abel, Amy Hankin et al.|Journal of Clinical Oncology|2026Cited by 0
Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.Ravi A. Madan, Melissa L. Abel, Esther Mena et al.|Journal of Clinical Oncology|2026Cited by 0